Equities research analysts expect that Natera Inc (NASDAQ:NTRA) will announce sales of $77.84 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Natera’s earnings, with the lowest sales estimate coming in at $75.93 million and the highest estimate coming in at $79.01 million. Natera posted sales of $67.00 million in the same quarter last year, which suggests a positive year-over-year growth rate of 16.2%. The firm is scheduled to report its next earnings results on Tuesday, March 10th.
According to Zacks, analysts expect that Natera will report full-year sales of $296.96 million for the current financial year, with estimates ranging from $295.01 million to $298.09 million. For the next fiscal year, analysts expect that the firm will post sales of $338.04 million, with estimates ranging from $330.97 million to $347.52 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that follow Natera.
Natera (NASDAQ:NTRA) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.20. The firm had revenue of $77.90 million for the quarter, compared to analysts’ expectations of $73.97 million. Natera had a negative net margin of 42.45% and a negative return on equity of 252.79%. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. During the same quarter last year, the business posted ($0.49) earnings per share.
A number of research analysts recently weighed in on the stock. BidaskClub raised shares of Natera from a “hold” rating to a “buy” rating in a report on Thursday. Zacks Investment Research lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Thursday. ValuEngine lowered shares of Natera from a “buy” rating to a “hold” rating in a report on Tuesday, December 3rd. Canaccord Genuity reissued a “buy” rating and issued a $44.00 target price on shares of Natera in a report on Wednesday, October 16th. Finally, Cowen raised their target price on shares of Natera from $30.00 to $42.00 and gave the company an “average” rating in a report on Friday, October 18th. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $41.67.
Shares of Natera stock traded down $1.12 on Monday, hitting $35.71. 558,478 shares of the company traded hands, compared to its average volume of 630,285. The business has a 50-day simple moving average of $35.34 and a 200 day simple moving average of $33.70. Natera has a 52 week low of $13.06 and a 52 week high of $40.92. The company has a debt-to-equity ratio of 1.20, a quick ratio of 2.26 and a current ratio of 2.35. The stock has a market capitalization of $2.77 billion, a P/E ratio of -19.20 and a beta of 1.35.
In other Natera news, CEO Steven Leonard Chapman sold 139,340 shares of Natera stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $35.00, for a total transaction of $4,876,900.00. Following the completion of the transaction, the chief executive officer now directly owns 32,540 shares of the company’s stock, valued at $1,138,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Michael Burkes Brophy sold 2,859 shares of Natera stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $38.25, for a total transaction of $109,356.75. Following the transaction, the chief financial officer now directly owns 16,630 shares of the company’s stock, valued at $636,097.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 312,255 shares of company stock valued at $11,303,217. 9.29% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. Orbimed Advisors LLC boosted its stake in Natera by 199.2% during the second quarter. Orbimed Advisors LLC now owns 3,224,328 shares of the medical research company’s stock worth $88,927,000 after buying an additional 2,146,742 shares during the period. BlackRock Inc. boosted its stake in Natera by 74.4% during the second quarter. BlackRock Inc. now owns 4,842,318 shares of the medical research company’s stock worth $133,552,000 after buying an additional 2,065,977 shares during the period. Millennium Management LLC boosted its stake in Natera by 1,562.8% during the third quarter. Millennium Management LLC now owns 2,191,733 shares of the medical research company’s stock worth $71,888,000 after buying an additional 2,059,920 shares during the period. Invesco Ltd. boosted its stake in Natera by 4,307.7% during the second quarter. Invesco Ltd. now owns 2,041,857 shares of the medical research company’s stock worth $56,314,000 after buying an additional 1,995,532 shares during the period. Finally, Nuveen Asset Management LLC purchased a new position in Natera during the second quarter worth $24,302,000. 84.93% of the stock is owned by institutional investors.
Natera Company Profile
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
See Also: How To Calculate Debt-to-Equity Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.